Multiple protein and pathway targets

The term 'Multiple protein and pathway targets' is a non-specific designation used to describe drugs that exhibit polypharmacology by interacting with several distinct biological entities (Nature Reviews Drug Discovery, 2019). It does not represent a single protein, receptor, or enzyme, but rather a collective pharmacological profile where efficacy is achieved through the modulation of a network of targets (Pharmacological Reviews, 2006). This approach is frequently utilized in the development of treatments for complex diseases like oncology, psychiatry, and systemic inflammation, where targeting a single molecule is often insufficient (Frontiers in Pharmacology, 2020). In clinical databases and trial registries, this term serves as a placeholder when a drug's mechanism involves a broad spectrum of activity across various pathways (ClinicalTrials.gov). Because it is an aggregate category, it lacks a specific molecular structure, chromosomal location, or unified biological function. The therapeutic challenge associated with this 'target' is the increased potential for off-target effects and the difficulty in pinpointing which specific interaction drives clinical benefit (Trends in Pharmacological Sciences, 2014). Consequently, while useful for high-level categorization, it is not a valid canonical name for a specific therapeutic target in molecular biology.

Other names

PolypharmacologyMulti-target drugsNetwork pharmacologyMulti-target ligands

Simultaneous modulation of multiple distinct molecular targets or biochemical pathways to achieve a therapeutic effect.